Search Results - "Carretta, Vito"

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial by Mangia, Alessandra, Minerva, Nicola, Bacca, Donato, Cozzolongo, Raffaele, Ricci, Giovanni L., Carretta, Vito, Vinelli, Francesco, Scotto, Gaetano, Montalto, Giuseppe, Romano, Mario, Cristofaro, Giuseppe, Mottola, Leonardo, Spirito, Fulvio, Andriulli, Angelo

“…It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as…”
Get full text

Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3 by Mangia, Alessandra, Santoro, Rosanna, Minerva, Nicola, Ricci, Giovanni L, Carretta, Vito, Persico, Marcello, Vinelli, Francesco, Scotto, Gaetano, Bacca, Donato, Annese, Mauro, Romano, Mario, Zechini, Franco, Sogari, Fernando, Spirito, Fulvio, Andriulli, Angelo

“…Patients with hepatitis C virus (HCV) genotype 2 or 3 were randomly assigned to a standard 24-week course of peginterferon and ribavirin or to therapy of…”
Get full text

Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience by Mangia, Alessandra, Cenderello, Giovanni, Orlandini, Alessandra, Piazzolla, Valeria, Picciotto, Antonio, Zuin, Massimo, Ciancio, Alessia, Brancaccio, Giuseppina, Forte, Paolo, Carretta, Vito, Zignego, Anna Linda, Minerva, Nicola, Brindicci, Gaetano, Marignani, Massimo, Baroni, Gianluca Svegliati, Bertino, Gaetano, Cuccorese, Giuseppe, Mottola, Leonardo, Ripoli, Maria, Pirisi, Mario

“…Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C Virus genotype…”
Get full text

An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response by Mangia, Alessandra, Thompson, Alexander J, Santoro, Rosanna, Piazzolla, Valeria, Tillmann, Hans L, Patel, Keyur, Shianna, Kevin V, Mottola, Leonardo, Petruzzellis, Daniela, Bacca, Donato, Carretta, Vito, Minerva, Nicola, Goldstein, David B, McHutchison, John G

“…Background & Aims Polymorphisms in the region of the interleukin (IL)-28B gene on chromosome 19 have been associated with peginterferon-alfa–induced clearance…”
Get full text

HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: the ITAL-C network study by Ippolito, Antonio Massimo, Milella, Michele, Messina, Vincenzo, Conti, Fabio, Cozzolongo, Raffaele, Morisco, Filomena, Brancaccio, Giuseppina, Barone, Michele, Santantonio, Teresa, Masetti, Chiara, Tundo, Paolo, Smedile, Antonina, Carretta, Vito, Gatti, Pietro, Termite, Antonio Patrizio, Valvano, Maria Rosa, Bruno, Giuseppe, Fabrizio, Claudia, Andreone, Pietro, Zappimbulso, Marianna, Gaeta, Giovanni Battista, Napoli, Nicola, Fontanella, Luca, Lauletta, Gianfranco, Cuccorese, Giuseppe, Metrangolo, Antonio, Francavilla, Ruggiero, Ciracì, Emanuela, Rizzo, Salvatore, Andriulli, Angelo

“…Abstract Background Sustained virological response (SVR12) rates at 12 weeks after treatment for HCV-infected patients with decompensated cirrhosis are used…”
Get full text

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection by Mangia, Alessandra, Minerva, Nicola, Bacca, Donato, Cozzolongo, Raffaele, Agostinacchio, Ernesto, Sogari, Fernando, Scotto, Gaetano, Vinelli, Francesco, Ricci, Giovanni Luciano, Romano, Mario, Carretta, Vito, Petruzzellis, Daniela, Andriulli, Angelo

“…In hepatitis C virus (HCV) genotypes 2 and 3 patients, the high rate of relapse after 12 to 16 weeks of antiviral therapy is the main concern for shortening…”
Get full text

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3 by Mangia, Alessandra, Bandiera, Franco, Montalto, Giuseppe, Mottola, Leonardo, Piazzolla, Valeria, Minerva, Nicola, Pellicelli, Adriano, Ricci, Giovanni L, Cela, Marina, Carretta, Vito, Scotto, Gaetano, Bacca, Donato, Annicchiarico, Brigida, Romano, Mario, Russello, Maurizio, Barbarini, Giorgio, Agostinacchio, Ernesto, Andriulli, Angelo

“…Background & Aims The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not…”
Get full text

Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study by Mottola, Leonardo, Cenderello, Giovanni, Piazzolla, Valeria A., Forte, Paolo, Carretta, Vito, Mecenate, Fabrizio, Brancaccio, Giuseppina, Minisini, Rosalba, Zuin, Massimo, Terreni, Natalia, Monti, Monica, Colombo, Alberto Eraldo, Nosotti, Lorenzo, Minerva, Nicola, Luzzitelli, Ilaria, Kostandini, Alba, Cuccorese, Giuseppe, Russello, Maurizio, Santoro, Rosanna, Mangia, Alessandra

“…Background & Aims Different prevalence of favourable IL28BCC genotype have been reported in studies performed in different countries around the world. Data on…”
Get full text

Hepatitis C and immigration: a multicentre study by Scotto, Gaetano, Armignacco, Orlando, Starnini, Giulio, Francavilla, Ruggiero, Foti, Giuseppe, Portelli, Vincenzo, Mazzeo, Maurizio, Minerva, Nicola, Carretta, Vito, Lo Muzio, Lorenzo, Fazio, Vincenzina

“…This retrospective multicentre study aims to evaluate the clinical and epidemiological features of HCV infection in a cohort of immigrants in Italy. Tests were…”
Get full text

RIBAVIRN DOSAGE IN HCV GENOTYPES 2 AND 3 PATIENTS COMPLETING SHORT THERAPY WITH PEG-INTERFERON ALFA-2B AND RIBAVIRIN by Mangia, Alessandra, Dalgard, Olav, Minerva, Nicola, Bacca, Donato, Ring-Larsen, Helmer, Copetti, Massimiliano, Carretta, Vito, Piazzolla, Valeria, Cozzolongo, Raffaele, Mottola, Leonardo

“…Background. Optimal dose of ribavirin to be used in combination with Peg-IFN in HCV genotype 2/3 patients undergoing short treatment has not been established…”
Get full text

Individualized Treatment of Genotype 1 Naive Patients: An Italian Multicenter Field Practice Experience: e110284 by Mangia, Alessandra, Cenderello, Giovanni, Orlandini, Alessandra, Piazzolla, Valeria, Picciotto, Antonio, Zuin, Massimo, Ciancio, Alessia, Brancaccio, Giuseppina, te, Paolo, Carretta, Vito

“…Background Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C…”
Get full text

A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C by Mangia, Alessandra, Minerva, Nicola, Annese, Mauro, Leandro, Gioacchino, Villani, Maria Rosaria, Santoro, Rosanna, Carretta, Vito, Bacca, Donato, Giangaspero, Antonio, Bisceglia, Michele, Ventrella, Francesco, Dell'Erba, G., Andriulli, Angelo

“…The aim of this study was to compare, in an open-label study, the efficacy and safety of a combination of interferon (IFN) and amantadine (AMA) with that of…”
Get full text

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis by Mangia, Alessandra, Santoro, Rosanna, Piattelli, Marisa, Leandro, Gioacchino, Minerva, Nicola, Annese, Mauro, Bacca, Donato, Spirito, Fulvio, Carretta, Vito, Ventrella, Francesco, Cela, Marina, Andriulli, Angelo

“…Background/Aims: The aim of the present, open-labelled, controlled study was to determine whether 5 MU of interferon (IFN) α2b combined with a standard dose of…”
Get full text

Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus : a randomized controlled trial by MANGIA, Alessandra, VILLANI, Maria Rosaria, ANDRIULLI, Angelo, MINERVA, Nicola, LEANDRO, Gioacchino, BACCA, Donato, CELA, Marina, CARRETTA, Vito, ATTINO, Vito, VENTRELLA, Francesco, GIANGASPERO, Antonio

“…In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages…”
Get full text

A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis by Mangia, Alessandra, Ricci, Giovanni, Minerva, Nicola, Persico, Marcello, Carretta, Vito, Bacca, Donato, Vinelli, Franco, Sogari, Giuseppe, Guadagnino, Vincenzo, Maio, Giovanni, Andriulli, Angelo

Get full text

Efficacy of 5 MU of interferon in combination with ribavirin for naı̈ve patients with chronic hepatitis C virus: a randomized controlled trial by Mangia, Alessandra, Villani, Maria Rosaria, Minerva, Nicola, Leandro, Gioacchino, Bacca, Donato, Cela, Marina, Carretta, Vito, Attino, Vito, Ventrella, Francesco, Giangaspero, Antonio, Andriulli, Angelo

Get full text